Biotechnology
GLOBAL FIRST "High-Definition Image": Decoding the "Code of Youth" - LivingPhoenix's POGMENT Collagen Breakthrough Fills Global Gap
CHENGDU, China, Sept. 11, 2025 /PRNewswire/ -- Recently, LivingPhoenix®Regenerative Technologies Development (Chengdu) Co., Ltd. (hereinafter "LivingPhoenix Technology") announced that its independently developed POGMENT triple-helix biomimetic collagen has, for the first time in the world, achi...
2025-09-11 21:27
2139
GLOBAL FIRST "High-Definition Image": Decoding the "Code of Youth" - LivingPhoenix's POGMENT Collagen Breakthrough Bridges International Gap
CHENGDU, China, Sept. 11, 2025 /PRNewswire/ -- Recently, LivingPhoenix®Regenerative Technologies Development (Chengdu) Co., Ltd., announced that its self-developed POGMENT triple-helix biomimetic collagen has, for the first time globally, achieved high-resolution molecular visualization of "coll...
2025-09-11 20:26
2039
YolTech Therapeutics Raises $45 Million in Series B Financing Led by AstraZeneca-CICC
SHANGHAI, Sept. 11, 2025 /PRNewswire/ -- YolTech Therapeutics, a clinical-stage biotech company pioneering in vivo genome editing therapies, today announced the closing of its approximately$45 million Series B financing led by the AstraZeneca-CICC healthcare investment fund. The proceeds will sup...
2025-09-11 20:05
1834
Kazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage IV HER2-Positive Breast Cancer with Paxalisib Monotherapy
SYDNEY, Sept. 11, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced new findings from a collaborative research program led by ProfessorSudha Rao at QIMR Berghofer. In this ex vivo study, blood samples from Stage IV HER2-...
2025-09-11 20:00
3053
Lundbeck showcases new clinical migraine data, including long-term preventive effectiveness of Vyepti® (eptinezumab) in patients severely impacted by migraine
* Lundbeck demonstrates leadership and unwavering commitment to advancing migraine management and supporting patient outcomes with six presentations at the 2025 International Headache Congress (IHC), including three oral presentations on eptinezumab (Vypeti®) and Lu AG09222 (anti-PACAP mAb) *...
2025-09-11 14:56
1475
HaemaLogiX wins "Most Promising CAR-T Pipeline in APAC" at the Asia Pacific CGT¹ Excellence Awards 2025
SYDNEY, Sept. 11, 2025 /PRNewswire/ -- HaemaLogiX Ltd, a clinical stage Australian biotech, developing novel immunotherapies for patients with blood cancers and B-cell diseases, was honoured to be awarded the"Most Promising CAR-T Pipeline in APAC" at the Asia Pacific CGT Excellence Awards 2025, h...
2025-09-11 11:52
1885
Amaran Biotech Wins Asia-Pacific Biologics CDMO Excellence Award for "Best Fill-Finish"
50-Person Team Demonstrates Taiwan's Biotech Strength HSINCHU, Sept. 11, 2025 /PRNewswire/ -- Amaran Biotech, a next-generation Contract Development and Manufacturing Organization (CDMO), was awarded the "Best Fill-Finish" at the 2025 Asia-Pacific Biologics CDMO Excellence Awards held inSingapore...
2025-09-11 10:00
2163
XingImaging in partnership with SynuSight was awarded a grant from The Michael J. Fox Foundation to support development of the α-synuclein PET tracer 18F-FD4 for Parkinson's disease
NEW HAVEN, Conn., Sept. 11, 2025 /PRNewswire/ -- XingImaging in partnership with SynuSight Biotech has received funding of$3.84M from The Michael J. Fox Foundation to conduct studies on18F-FD4, a specific α-synuclein (α-syn)-targeted PET tracer. Based on prior investigator-initiated trials, the ...
2025-09-11 05:06
1049
C-Ray Therapeutics Supports Mednovo's Phase III Clinical Trial with First Patient Dosed for Lutetium [177Lu] Oxodotreotide Injection
CHENGDU, China, Sept. 10, 2025 /PRNewswire/ -- August 22, 2025, Mednovo Group Co., Ltd. ("Mednovo") announced that the first patient has been successfully dosed in its Phase III clinical trial of Lutetium [177Lu] Oxodotreotide Injection, a Class 3 targeted radiotherapeutic drug. As the exclusive...
2025-09-10 21:30
1157
Shineco Achieves Mass Production of High-Purity Physical Phospholipids, Breaking Foreign Monopoly and Unlocking Innovation Across Industries
BEIJING, Sept. 10, 2025 /PRNewswire/ -- Shineco Inc. (NASDAQ: SISI) ("Shineco" or the "Company"), a leading developer of induced pluripotent stem cell (iPSC) technology platforms, today announced that its subsidiary, Fuzhou Meidashan Biotechnology Co., Ltd., has successfully achieved large-scale ...
2025-09-10 21:30
1242
LakeShore Biopharma Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee
BEIJING, Sept. 10, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB, "LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious ...
2025-09-10 20:10
1408
ImmVira Announces First-in-Human Data of Engineered Exosome MVR-EX105 for Fat Reduction and Muscle Preservation by Topical Application at 2025 Annual Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders
SUZHOU, China, Sept. 9, 2025 /PRNewswire/ -- ImmVira Group ("ImmVira" or the "Company") recently announced that its lead engineered exosome candidate, MVR-EX105 ("EX105") is featured in a poster presentation at the 2025 Annual Congress of the International Federation for the Surgery of Obesity an...
2025-09-10 10:49
1201
Cadonilimab(PD-1/CTLA-4) plus Pulocimab (VEGFR-2) Combination Therapy Shows Promising Results in IO-Resistant Non-Small Cell Lung Cancer in Oral Presentation at the 2025 WCLC
HONG KONG, Sept. 9, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) announced that data from a Phase Ib/II clinical study evaluating the combination of cadonilimab and pulocimab (an anti-VEGFR-2 antibody) in patients with immunotherapy (IO)-resistant NSCLC were presented in a Mini Oral session at the ...
2025-09-10 10:40
1266
Telix Doses First Patient in Phase 3 BiPASS Trial: PSMA-PET Imaging for Prostate Cancer Diagnosis
MELBOURNE, Australia and INDIANAPOLIS, Sept. 10, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces it has dosed the first patient in a Phase 3 clinical trial aimed at expanding the indications for Illuccix® and Gozellix® (kits for the preparation ...
2025-09-10 07:01
1514
TCI Biotech Strengthens Global Leadership Team with Appointment of Sales VP Tony Hatori and Strategic Consultant Alan Roberts
SALT LAKE CITY, Utah, Sept. 9, 2025 /PRNewswire/ -- TCI, a global biotechnology leader in health and wellness innovation, today announced key leadership appointments to accelerate its international growth.Tony Hatori has been named Vice President of Sales, whileAlan Roberts joins as Strategic Con...
2025-09-09 23:00
1847
iRegene Therapeutics Secures Series B+ Financing Following FDA Fast Track Designation for its Flagship Product NouvNeu001
CHENGDU, China, Sept. 9, 2025 /PRNewswire/ -- iRegene Therapeutics (Chengdu) Co., Ltd. ("iRegene" or the "Company"), a biotechnology company pioneering chemically induced allogeneic cell therapy, announced on September 4th the successful completion of its Series B+ financing round, co-led by Nort...
2025-09-09 21:00
1346
XtalPi AI Drug Discovery Collaboration Reaches Milestone as PharmaEngine's Novel PRMT5 Inhibitor PEP08 Receives Clinical Trial Approvals
SHENZHEN, China, Sept. 9, 2025 /PRNewswire/ -- XtalPi Inc. (Stock Code: 2228.HK) has announced that PEP08, a next-generation PRMT5 inhibitor candidate developed through its AI drug discovery collaboration with PharmaEngine, Inc. (TWO:4162), has received regulatory clearances to initiate Phase 1 c...
2025-09-09 20:42
2522
BON Announces $18 Million Cooperation Agreement for Innovative Second-Generation Apple Series Health Products
XI'AN, China, Sept. 9, 2025 /PRNewswire/ -- Bon Natural Life Limited (NASDAQ: BON) ("BON" or the "Company"), a leading bio-ingredient solution provider in the natural, health and personal care industry, today announced it has entered into a non-exclusive cooperation agreement with Beijing Huahai ...
2025-09-09 20:30
2535
Dizal Showcases Robust Portfolio of Lung Cancer Studies at 2025 WCLC
SHANGHAI, Sept. 9, 2025 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced the presentation of new findings on its leading assets, ZEGFROVY® (sunvozertinib) and golidocitinib, in...
2025-09-09 18:00
1309
WuXi Biologics Launches Green CRDMO White Paper to Advance Sustainability in Biologics Industry
* End-to-end Green CRDMO solutions to enable global clients for broader positive impact * Span from biologics research, development, manufacturing, and overall operations * Integration with lean management and digitalization for continuous excellence * A comprehensive ecosystem featuring ...
2025-09-09 18:00
2764
Week's Top Stories
Most Reposted
Agoda Launches Agoda Impact Lab at ASEAN Tourism Forum
[Picked up by 318 media titles]
2026-01-29 15:06
Agoda Launches Open-Source API Agent to Simplify MCP Server Integrations
[Picked up by 309 media titles]
2026-01-27 13:00
Nokia Strengthens Edge AI Capabilities Through Strategic Collaboration with Blaize on Hybrid Inference Solutions Across Asia Pacific Regions
[Picked up by 294 media titles]
2026-01-27 18:00
Multi-Award Winning Phuket Marriott Resort & Spa, Merlin Beach: Voted Top 3 Best Family Resort
[Picked up by 283 media titles]
2026-01-30 08:00
True 1000Hz Powerhouse: PHILIPS EVNIA Unleashes the World's First 1000Hz Dual-Mode Gaming Monitor 27M2N5500XD
[Picked up by 282 media titles]
2026-01-29 18:03
